3 days Ago By ABMN Staff
Voyager Therapeutics ( NASDAQ:VYGR – Get Free Report ) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. Several other research firms have also weighed in on VYGR.
Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $30.
00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Wedbush dropped their price objective on Voyager Therapeutics from $8.
00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th.
They issued an “outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock.
According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $17.00.
Check Out Our Latest Report on Voyager Therapeutics Voyager Therapeutics Stock Down 2.1 % Voyager Therapeutics ( NASDAQ:VYGR – Get Free Report ) last released its earnings results on Tuesday, November 12th. The company reported ($0.
16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29.
Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.
The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million.
During the same quarter in the prior year, the firm posted ($0.59) earnings per share. Research analysts anticipate that Voyager Therapeutics will post -1.
12 earnings per share for the current fiscal year. Insider Buying and Selling In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.
82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.
82. This trade represents a 6.52 % decrease in their position.
The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Company insiders own 4.53% of the company’s stock.
Hedge Funds Weigh In On Voyager Therapeutics Several hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its holdings in Voyager Therapeutics by 55.8% during the third quarter.
Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares during the last quarter. Geode Capital Management LLC lifted its position in Voyager Therapeutics by 0.6% during the 3rd quarter.
Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $6,192,000. Verition Fund Management LLC acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $216,000.
Finally, BNP Paribas Financial Markets grew its holdings in shares of Voyager Therapeutics by 30.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock valued at $288,000 after acquiring an additional 11,516 shares in the last quarter.
48.03% of the stock is owned by institutional investors. About Voyager Therapeutics ( Get Free Report ) Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases.
The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. Further Reading Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
